The role of DPP4i in diabetic HFpEF Unlike GLP-1 RA and SGLT2i, DPP4i, a relatively new class of anti-diabetic drugs, have aroused controversy due to inconsistency about their cardiovascular effects in diabetic HFpEF (Table 4)
doi: 10.1016/j.biopha.2024.116485, 26
Mar 2017;274(3):1245-1250
Supplier pricing, vial sizes, and purity all affect cost
In a 2022 study, Santoro found that after 16 weeks of exercise, meal control, and the over-the-counter drug orlistat (Alli), we did not see an improvement in pregnancy rate. In a similar 2016 study in the Netherlands, the weight-loss intervention resulted in a slight decrease in the pregnancy rate
Although this is an attractive approach that spurred great interest, caution should be exercised as standard dosing may be a challenge depending on individual inhalation technique